Adiponectin, insulin sensitivity, β-cell function, and racial/ethnic disparity in treatment failure rates in TODAY

Diabetes Care

Volumn 40, Issue 1, 2017, Pages 85-93

  Arslanian, Silva ^a   El Ghormli, Laure ^b   Bacha, Fida ^c   Caprio, Sonia ^d   Goland, Robin ^e   Haymond, Morey W ^c   Levitsky, Lynne ^f   Nadeau, Kristen J ^g   White, Neil H ^h   Willi, Steven M ⁱ  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C PEPTIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ADIPOQ PROTEIN, HUMAN; ANTIDIABETIC AGENT; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; THIAZOLE DERIVATIVE;

ADOLESCENT; ARTICLE; BLACK PERSON; CAUCASIAN; CELL FUNCTION; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ETHNIC DIFFERENCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; ETHNIC GROUP; ETHNOLOGY; GLUCOSE TOLERANCE TEST; HEALTH DISPARITY; HISPANIC; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE;

ADIPONECTIN; ADOLESCENT; AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOSE TOLERANCE TEST; HEALTH STATUS DISPARITIES; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; MALE; METFORMIN; THIAZOLES; TREATMENT FAILURE;

EID: 85008169601     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0455     Document Type: Article

References (42)

1. TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247-2256
2. Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in African-American children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes 2002;51:3014-3019
3. Hannon TS, Bacha F, Lin Y, Arslanian SA. Hyperinsulinemia in African-American adolescents compared with their American white peers despite similar insulin sensitivity: A reflection of upregulated b-cell function? Diabetes Care 2008;31:1445-1447
4. Bacha F, Gungor N, Lee S, Arslanian SA. Type 2 diabetes in youth: are there racial differences in b-cell responsiveness relative to insulin sensitivity? Pediatr Diabetes 2012;13:259-265
5. Weiss R, Dziura JD, Burgert TS, Taksali SE, Tamborlane WV, Caprio S. Ethnic differences in beta cell adaptation to insulin resistance in obese children and adolescents. Diabetologia 2006;49:571-579
6. Wagner JA, Wright EC, Ennis MM, et al. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin Pharmacol Ther 2009;86:619-625
7. Lee S, Bacha F, Gungor N, Arslanian SA. Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care 2006;29:51-56
8. Bush NC, Darnell BE, Oster RA, Goran MI, Gower BA. Adiponectin is lower among African Americans and is independently related to insulin sensitivity in children and adolescents. Diabetes 2005;54:2772-2778
9. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. Metabolism 2004;53:1-3
10. Copeland KC, Zeitler P, Geffner M, et al.; TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: The TODAY cohort at baseline. J Clin Endocrinol Metab 2011;96:159-167
11. Zeitler P, Epstein L, Grey M, et al.; TODAY Study Group. Treatment options for type 2 diabetes in adolescents and youth: A study of the comparative efficacy of metformin alone or in combinationwith rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007;8:74-87
12. Rutkowski JM, Scherer PE. Isolation and quantitation of adiponectin higher order complexes. Methods Enzymol 2014;537:243-259
13. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012;55:2319-2326
14. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357-1362
15. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedionemediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152-12162
16. Arslanian S, Pyle L, Payan M, et al.; TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and b-cell function in TODAY. Diabetes Care 2013;36:1749-1757
17. George L, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S. Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes. J Clin Endocrinol Metab 2011; 96:2136-2145
18. Sjaarda LG, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S. Oral disposition index in obese youth from normal to prediabetes to diabetes: relationship to clamp disposition index. J Pediatr 2012;161:51-57
19. Cox DR. Regression models and life-tables. JRSS (B) 1972;74:187-220
20. Rothman RL, Mulvaney S, Elasy TA, et al. Self-management behaviors, racial disparities, and glycemic control among adolescents with type 2 diabetes. Pediatrics 2008;121:e912-e919
21. Gardener H, Crisby M, Sjoberg C, et al. Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. Metab Syndr Relat Disord 2013;11:46-55
22. Schuster DP, Kien CL, Osei K. Differential impact of obesity on glucose metabolism in black and white American adolescents. Am J Med Sci 1998;316:361-367
23. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2004;53:2473-2478
24. Mather KJ, Funahashi T, Matsuzawa Y, et al.; Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008;57:980-986
25. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013;2:133-141
26. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935
27. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S. Youth type 2 diabetes: insulin resistance, b-cell failure, or both? Diabetes Care 2005;28:638-644
28. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 2004;27:547-552
29. Bacha F, Saad R, Gungor N, Arslanian SA. Does adiponectin explain the lower insulin sensitivity and hyperinsulinemia of African-American children? Pediatr Diabetes 2005;6:100-102
30. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-2974
31. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptorgamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380
32. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008;10:1204-1211
33. Derosa G, Franzetti IG, Querci F, et al. Exenatide plus metformin compared with metformin alone on b-cell function in patientswith type 2 diabetes. Diabet Med 2012;29:1515-1523
34. Esteghamati A, Azizi R, Ebadi M, et al. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesionmolecule concentrations in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. Exp Clin Endocrinol Diabetes 2015;123:289-295
35. Wang H, Ni Y, Yang S, Li H, Li X, Feng B. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. Curr Ther Res Clin Exp 2013;75:88-92
36. Miazgowski T, Dziwura-Ogonowska J, Safranow K, Iskierska K, Widecka K. Changes in adiponectin level and fat distribution in patients with type 2 diabetes. Eur J Clin Invest 2014;44: 192-199
37. Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab 2012; 25:41-49
38. Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008;9:567-576
39. Gómez-Díaz RA, Talavera JO, Pool EC, et al. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: A placebo-controlled randomized clinical trial. Metabolism 2012;61: 1247-1255
40. Fu JF, Liang L, Zou CC, et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes 2007;31:15-22
41. Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance-effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab 2012;25:33-40
42. Clarson CL, Mahmud FH, Baker JE, et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine 2009;36:141-146